Xenter
It develops a TechMed platform for healthcare organizations, using AI-oriented medical technology to support clinical workflows and commercialization.
Overview
Xenter is building and commercializing its TechMed platform, a healthcare technology offering positioned at the intersection of medical devices, digital health and AI. The company targets clinical and medical-technology markets seeking tools that can modernize care delivery and related workflows. The company raised $58.25 million in Series B financing in July 2026, bringing total disclosed funding to about $58 million. The round is intended to accelerate commercial expansion of the platform, indicating a shift from development toward broader market adoption.
Funding History
Xenter Closes Series B Financing, Raising $58.25 Million to Accelerate Commercial Expansion of its TechMed™ Platform
Frequently Asked Questions
- How much funding does AI Funding track for Xenter?
- AI Funding tracks $58M for Xenter across 1 funding round in this database.
- What does Xenter do?
- Xenter is building and commercializing its TechMed platform, a healthcare technology offering positioned at the intersection of medical devices, digital health and AI. The company targets clinical and medical-technology markets seeking tools that can modernize care delivery and related workflows. The company raised $58.25 million in Series B financing in July 2026, bringing total disclosed funding to about $58 million. The round is intended to accelerate commercial expansion of the platform, indicating a shift from development toward broader market adoption.
- Where is Xenter headquartered?
- Xenter is headquartered in Salt Lake City, United States.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.